Cetuximab in metastatic or recurrent head and neck cancer: The EXTREME trial

Expert Review of Anticancer Therapy

Volumn 9, Issue 10, 2009, Pages 1421-1428

  Rivera, Fernando ^a   García Castaño, Almudena ^a   Vega, Noelia ^a   Vega Villegas, Maria Eugenia ^a   Gutiérrez Sanz, Lourdes ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Cetuximab; EXTREME trial; Head cancer; Metastatic disease; Neck cancer; Recurrent disease

Indexed keywords

B RAF KINASE; BEVACIZUMAB; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; K RAS PROTEIN; LAPATINIB; METHOTREXATE; NIMOTUZUMAB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; SORAFENIB; SUNITINIB;

ADVANCED CANCER; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG FATALITY; DYSPHAGIA; HEAD AND NECK CANCER; HEALTH STATUS; HUMAN; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECURRENT CANCER; SEPSIS; SKIN MANIFESTATION; SPEECH DISORDER; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 70350582832     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.113     Document Type: Article

References (59)

1. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 19, 5548-5557 (2000).
2. Harari PM, Huang SM. Searching for reliable epidermal growth factor receptor response predictors. Clin. Cancer Res. 10, 691-700 (2004).
3. Chung CH, Ely K, McGavran L et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J. Clin. Oncol. 24(25), 4170-4176 (2006). (Pubitemid 46622295)
4. Dassonville O, Formento JL, Francoual M et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J. Clin. Oncol. 11, 1873-1878 (1993).
5. Hitt R, Ciruelos E, Amador ML et al. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur. J. Cancer 41(3), 453-460 (2005). (Pubitemid 40187218)
6. Baselga J. Targeting the epidermal growth factor receptor: a clinical reality. J. Clin. Oncol. 19(Suppl. 18), S41-S44 (2001). (Pubitemid 32880078)
7. Nyati MK, Morgan MA, Feng FV, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat. Rev. Cancer 6, 876-885 (2006).
8. Waksal HW. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev. 18, 427-436 (1999).
9. Bier H, Hoffmann T, Haas I, van Lierop A. Anti(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol. Immunother. 46, 167-173 (1998). (Pubitemid 28239882)
10. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N. Engl. J. Med. 354(6), 567-578 (2006). • Demonstrated that cetuximab has a clear role in the treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN). (Pubitemid 43209104)
11. Curran D, Giralt J, Harari PM et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J. Clin. Oncol. 25(16), 2191-2197 (2007). (Pubitemid 46954642)
12. Bonner JA, Harari PM, Giralt J et al. Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx. ASCO Annual Meeting Proceedings. J. Clin. Oncol. 23(16S), (2005) (Abstract 5533).
13. Vermorken JB. Medical treatment in head and neck cancer. Ann. Oncol. 16(Suppl. 2), ii258-ii264 (2005). • Interesting review of the role of systemic treatments in SCCHN.
14. Forastiere AA, Metch B, Schuller DE et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J. Clin. Oncol. 10(8), 1245-1251 (1992).
15. Jacobs C, Lyman G, Velez-Garcia E et al. A Phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol. 10(2), 257-263 (1992).
16. Liverpool Head and Neck Oncology Group. A Phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Br. J. Cancer 61(2), 311-315 (1990).
17. Clavel M, Vermorken JB, Cognetti F et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A Phase III study of the EORTC head and neck cancer cooperative group. Ann. Oncol. 5(6), 521-526 (1994). (Pubitemid 24223504)
18. Choong N, Vokes E. Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J. Clin. 58(1), 32-53 (2008). • Interesting review of the role of systemic treatments in SCCHN.
19. Worden FP, Moon J, Samlowski W et al. A Phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007. Cancer 107(2), 319-327 (2006). (Pubitemid 44036561)
20. Janinis J, Papadakou M, Xidakis E et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a Phase II feasibility study. Am. J. Clin. Oncol. 23(2), 128-131 (2000).
21. Shin DM, Khuri FR, Glisson BS et al. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 91(7), 1316-1323 (2001).
22. Baselga J, Trigo JM, Bourhis J et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23(24), 5568-5577 (2005). (Pubitemid 46300151)
23. Herbst RS, Arquette M, Shin DM et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23(24), 5578-5587 (2005). (Pubitemid 46300152)
24. Vermorken JB, Trigo J, Hitt R et al. Open-label, uncontrolled, multicenter Phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol. 25(16), 2171-2177 (2007). • This trial found an interesting activity of cetuximab in monotherapy for platinum-refractory metastatic and/or recurrent SCCHN. Based on this trial, the US FDA approved the indication of cetuximab monotherapy for patients with recurrent or metastatic SCCHN refractory to cisplatin. (Pubitemid 46954639)
25. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo versus cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 23, 8646-8654 (2005). • First randomized trial exploring the addition of cetuximab to chemotherapy in first-line treatment of metastatic/recurrent SCCHN. Although this trial was underpowered to demonstrate an effect on either progression-free survival or survival, it found an improvement in the response rate that suggested an additive effect of cetuximab and cisplatin. (Pubitemid 46211507)
26. Bourhis J, Rivera F, Mesia R et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 24(18), 2866-2872 (2006). • Found an interesting efficacy and tolerance of this combination and no statistically significant differences were seen between patients treated with cisplatin or carboplatin. The experimental arm of the Erbitux in First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer (EXTREME) trial was based on this trial. (Pubitemid 46630587)
27. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359(11), 1116-1127 (2008). •• This is the manuscript of the EXTREME trial and is the most important reference in this review.
28. Rivera-Herrero F, Hitt R, Kawecki A et al. Cetuximab plus platinum-based therapy first-line in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: a quality of life analysis of the EXTREME trial. ESMO Ann Oncol. 19(Suppl. 8), vii 219 (abstract 693PD) (2008). • Preliminary data concerning the quality of life analysis of the EXTREME trial. The manuscript with the final results of this analysis is currently under preparation and will be available in the next few months.
29. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Störkel S. Inmunohistochemical detection of EGFR in paraffin-embedded tumour tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J. Histochem. Cytochem. 52, 893-901 (2004). (Pubitemid 38857154)
30. Dei Tos AP, Ellis I. Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? Eur. J. Cancer 41, 1383-1392 (2005). (Pubitemid 40826461)
31. Younes M. Is immunohistochemistry for epidermal growth factor receptor expression a poor predictor of response to epidermal growth factor receptor-targeted therapy? J. Clin. Oncol. 23, 923. Reply: Saltz L, 923-924 (2005). (Pubitemid 46224198)
32. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on cancer stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92, 1331-1346 (2001).
33. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumours does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J. Clin. Oncol. 22, 4772-4778 (2004). (Pubitemid 41185088)
34. Defize LH, Boonstra J, Meisenhelder J et al. Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors. J. Cell Biol. 109, 2495-2507, (1989). (Pubitemid 19282633)
35. Bellot F, Moolenaar W, Kris R et al. High-affinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses. J. Cell Biol. 110, 491-502 (1990). (Pubitemid 20067592)
36. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27(5), 663-671 (2009).
37. Van Cutsem E, Lang I, D'haens G et al. K-RAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. ASCO Annual Meeting Proceedings. J. Clin. Oncol. 26(15S), (2008) (Abstract 2).
38. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-RAS mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
39. Amado RG, Wolf M, Peeters M et al. Wild-type K-RAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008).
40. Licitra L, Rolland F, Bokemeyer C et al. Biomarker potential of EGFR gene copy number by FISH in the Phase III EXTREME study: platinum-based CT plus cetuximab in first-line R/M SCCHN. ASCO Annual Meeting Proceedings. J. Clin. Oncol. 27(15S), (2009) (Abstract 6005).
41. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26(35), 5705-5712 (2008).
42. Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6, 279-286 (2005). (Pubitemid 40590264)
43. Sartore-Bianchi A, Moroni M, Veronese S et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J. Clin. Oncol. 25(22), 3238-3245 (2007). (Pubitemid 47325607)
44. Lièvre A, Bachet JB, Le Corre D et al. K-RAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66(8), 3992-3995 (2006).
45. Romagnani E, Martin V, Ghisletta M et al. EGFR gene status, K-RAS mutation and PTEN expression predict cetuximab response in metastatic colorectal cancer (mCRC). Gastrointestinal Cancers Symposium Orlando, FL, USA 19-21 January 2007 (Abstract 427) (2007).
46. Personeni N, De Schutter J, De Hertogh G et al. Response prediction to cetuximab-based therapy: the role of EGFR copy number by fluorescence in situ hybridization and downstream effectors gene mutations. Gastrointestinal Cancers Symposium Orlando, FL, USA 19-21 January 2007 (Abstract 400).
47. Finocchiaro G, Cappuzzo F, Jänne PA et al. EGFR, HER2 and K-RAS as predictive factors for cetuximab sensitivity in colorectal cancer. ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25(18S), (2007) (Abstract 4021).
48. Sartore-Bianchi A, Martini M, Molinari F et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 69(5), 1851-1857 (2009).
49. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-RAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25(22), 3230-3237 (2007). (Pubitemid 47325606)
50. Forastiere AA, Burtness BA. Epidermal growth factor receptor inhibition in head and neck cancer - more insights, but more questions. J. Clin. Oncol. 25(16), 2152-2155 (2007).
51. RTOG 0522: a randomized Phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab (followed by surgery for selected patients) for stage III and IV head and neck carcinomas. Adv. Hematol. Oncol. 5(2), 79-81(2007).
52. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 22(1), 77-85 (2004). (Pubitemid 41095117)
53. Kirby AM, A'Hern RP, D'Ambrosio C et al. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br. J. Cancer 94(5), 631-636 (2006). (Pubitemid 43361892)
54. Abidoye OO, Cohen EE, Wong SJ et al. A Phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). ASCO Annual Meeting Proceedings. J. Clin. Oncol. 24(18S), (2006) (Abstract 5568).
55. Williamson SK, Moon J, Huang CH et al. A Phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): a Southwest Oncology Group (SWOG) trial. ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25(18S), (2007) (Abstract 6044).
56. Choong NW, Cohen EE, Kozloff MF et al. Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). ASCO Annual Meeting Proceedings. J. Clin. Oncol. 26(15S), (2008) (Abstract 6064).
57. Pfister DG, Lee NY, Sherman E et al. Phase II study of bevacizumab (B) plus cisplatin (C) plus intensity-modulated radiation therapy (IMRT) for locoregionally advanced head and neck squamous cell cancer (HNSCC): preliminary results. ASCO Annual Meeting Proceedings. J. Clin. Oncol. 27(15S), (2009) (Abstract 6013).
58. Wagenblast J, Hambek M, Baghi M et al. Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines. Anticancer Res. 28(2A), 687-692 (2008). (Pubitemid 351578909)
59. Wagenblast J, Baghi M, Arnoldner C et al. Cetuximab enhances the efficacy of bortezomid in squamous cell carcinoma cell lines. J. Cancer Res. Clin. Oncol. 135(3), 387-393 (2009).